Get the Stockscreener App
1,010.31
0.41%
-4.18
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,010.31, with a volume of 2.49M.
It is down -0.41% in the last 24 hours and up +9.13% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,014.49
Open:
$1023.84
24h Volume:
2.49M
Relative Volume:
0.66
Market Cap:
$904.25B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
49.97
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-6.06%
1M Performance:
+9.13%
6M Performance:
+31.95%
1Y Performance:
+22.37%
1-Day Range:
$1,004.00
$1,027.39
1-Week Range:
$1,004.00
$1,084.15
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
How Eli Lilly is Tackling Health Literacy and Sustainability - Healthcare Digital
Eli Lilly, Pfizer land on China’s first private insurance list - BusinessLine
Eli Lilly, Pfizer Secure Inclusion in Chinese Private Health Insurance Catalog - marketscreener.com
Eli Lilly, Pfizer Land on China’s First Private Insurance List - Bloomberg.com
Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip? - AOL.com
Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip? - The Motley Fool
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Is It Too Late To Consider Eli Lilly After Its Massive Multi Year Share Price Surge - simplywall.st
Eli Lilly Among 4 Medical Newcomers To IBD Top Growth Stock Lists - Investor's Business Daily
With Eli Lilly Stock Sliding, Have You Assessed The Risk? - Trefis
Eli Lilly shares fell for seven consecutive sessions - MSN
A look into Eli Lilly’s sustainability efforts and what it suggests about the trend in Big Pharma - Healthcare Brew
Eli Lilly doctor explains how weight-loss medication Zepbound works - Fox 59
Eli Lilly, Indiana University enter $40 million clinical trial agreement - 95.3 MNC
Eli Lilly's Options Frenzy: What You Need to Know - Benzinga
Eli Lilly lowers price of Zepbound single-dose vials - Drug Store News
Eli Lilly and Company: Making Healthcare Accessible For All - Sustainability Magazine
Compounding pharmacy Strive to occupy 350,000 square feet in Mesa while fighting Big Pharma - The Business Journals
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi - The Globe and Mail
Is It Too Late To Consider Eli Lilly After Its Massive Five Year Share Price Surge? - Yahoo Finance
TheWrap, Eli Lilly and Company Toast Dr. Stacy L. Smith With VIP Beverly Hills Dinner | Photos - TheWrap
BMO Capital Maintains Eli Lilly and (LLY) Outperform Recommendation - Nasdaq
IU, Eli Lilly ink partnership for clinical trials - WFYI
Lilly and IU announce $40M partnership to expand clinical trial access - Indianapolis Recorder
Eli Lilly and Company (LLY): A bull case theory - MSN
Eli Lilly and Company (LLY): A Bull Case Theory - Finviz
Lilly, IU sign clinical trial, research agreement worth up to $40M - dailyjournal.net
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock - Yahoo Finance
A deal with Donald Trump is boosting this pharma giant - Investors' Chronicle
Eli Lilly (LLY): BMO Capital Raises Price Target, Maintains Rati - GuruFocus
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
Eli Lilly stock price target raised to $1,200 by BMO on obesity drug outlook - Investing.com Canada
Eli Lilly $1 trln value is bet on Coke-like future - Breakingviews
BMO Capital Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Outperform Rating - marketscreener.com
FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL - Pharmaceutical Business review -
Eli Lilly, IU agree to $40 million agreement to expand clinical trials - IndyStar
Eli Lilly And Indiana University Sign $40 Mln Agreement To Expand Clinical Trials In Indiana - Nasdaq
Lilly, Indiana University launch new partnership - WTHR
Eli Lilly, Indiana University launch new partnership - WTHR
Eli Lilly’s Jaypirca Granted Traditional FDA Approval In Treating Certain Cancers - Stocktwits
Lilly Announces Changing The Thread Collection Campaign - InkFreeNews.com
Tag Archives: Changing the Thread Collection - InkFreeNews.com
Lilly and IU partner to enhance clinical trials and treatments for Hoosiers - WISH-TV
Lilly, IU Boost Hoosier Access to Trials, Treatments - Mirage News
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers - News at IU
Eli Lilly and Company (LLY) Stock: Gains Expanded FDA Approval for Jaypirca - CoinCentral
1 reason to buy Eli Lilly hand over fist before the new year - MSN
Eli Lilly (LLY) Gains FDA Approval for Expanded Use of Jaypirca - GuruFocus
As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock? - Barchart.com
Morgan Stanley Bullish on Eli Lilly and Company (LLY) - MSN
Eli Lilly announces FDA approval of expanded indication for Jaypirca - TipRanks
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):